Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1291772 | 0.84 | LMNA (0.42) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL9156477 | 0.83 | SMYD2 (0.41) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL29102862 | 0.82 | SMYD2 (0.38) | SMYD2HTTCYP3A4SMN1; SMN2PPARA | |
| SCHEMBL3078638 | 0.81 | L3MBTL1 (0.43) | HTTCYP3A4SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL1291773 | 0.81 | LMNA (0.40) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL26264744 | 0.81 | SMYD2 (0.38) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL18647042 | 0.79 | SMYD2 (0.40) | SMYD2HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL20296763 | 0.79 | SMYD2 (0.37) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL12438032 | 0.79 | SMYD2 (0.37) | SMYD2HTTCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL12438035 | 0.79 | SMYD2 (0.37) | SMYD2HTTCYP3A4SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | SMYD2 1094/4885HTT 2824/4885CYP3A4 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.